RemeGen Statistics

Total Valuation

RemeGen has a market cap or net worth of EUR 6.34 billion. The enterprise value is 6.46 billion.

Market Cap	6.34B
Enterprise Value	6.46B

Important Dates

The next estimated earnings date is Saturday, March 28, 2026.

Earnings Date	Mar 28, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	200.81M
Shares Outstanding	n/a
Shares Change (YoY)	+0.77%
Shares Change (QoQ)	+4.08%
Owned by Insiders (%)	12.41%
Owned by Institutions (%)	44.15%
Float	463.67M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	23.77
PB Ratio	22.82
P/TBV Ratio	24.45
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-56.94
EV / Sales	24.06
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-167.22

Financial Position

The company has a current ratio of 0.96, with a Debt / Equity ratio of 0.94.

Current Ratio	0.96
Quick Ratio	0.66
Debt / Equity	0.94
Debt / EBITDA	n/a
Debt / FCF	-6.76
Interest Coverage	-12.31

Financial Efficiency

Return on equity (ROE) is -40.42% and return on invested capital (ROIC) is -12.08%.

Return on Equity (ROE)	-40.42%
Return on Assets (ROA)	-9.72%
Return on Invested Capital (ROIC)	-12.08%
Return on Capital Employed (ROCE)	-28.90%
Revenue Per Employee	88,933
Profits Per Employee	-37,829
Employee Count	2,999
Asset Turnover	0.38
Inventory Turnover	0.53

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	n/a
Average Volume (20 Days)	46

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, RemeGen had revenue of EUR 266.71 million and -113.45 million in losses. Loss per share was -0.21.

Revenue	266.71M
Gross Profit	222.11M
Operating Income	-108.78M
Pretax Income	-113.45M
Net Income	-113.45M
EBITDA	-76.20M
EBIT	-108.78M
Loss Per Share	-0.21

Full Income Statement

Balance Sheet

The company has 141.22 million in cash and 261.34 million in debt, with a net cash position of -120.11 million.

Cash & Cash Equivalents	141.22M
Total Debt	261.34M
Net Cash	-120.11M
Net Cash Per Share	n/a
Equity (Book Value)	277.76M
Book Value Per Share	0.50
Working Capital	-13.61M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -7.44 million and capital expenditures -31.19 million, giving a free cash flow of -38.63 million.

Operating Cash Flow	-7.44M
Capital Expenditures	-31.19M
Free Cash Flow	-38.63M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 83.28%, with operating and profit margins of -40.79% and -42.54%.

Gross Margin	83.28%
Operating Margin	-40.79%
Pretax Margin	-42.54%
Profit Margin	-42.54%
EBITDA Margin	-28.57%
EBIT Margin	-40.79%
FCF Margin	n/a

Dividends & Yields

RemeGen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.77%
Shareholder Yield	-0.77%
Earnings Yield	-1.79%
FCF Yield	-0.61%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RemeGen has an Altman Z-Score of 2.83 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.83
Piotroski F-Score	4